Trident Lifeline Ltd operates in India's pharma sector with ₹323.98 Cr market cap. Latest quarter revenue of ₹14.74 Cr grew 70.6% YoY with 27.69% operating margins. Shows strong execution in domestic pharma markets.
Generated analysis · source review pending
Generated analysis · source review pending
856 historical price candles were omitted because the exchange source has not been verified.
No red flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM | ₹1,61,325 Cr | ₹1,76,123 Cr | ₹15,723 Cr | ₹5,191 Cr | 32.6% | ₹2,181 Cr | 15.3% | 14.5% | 27.1% | 163 |
| Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE | ₹1,14,284 Cr | ₹1,26,053 Cr | ₹28,592 Cr | ₹8,316 Cr | 31.2% | ₹4,513 Cr | 18.9% | 23.4% | 19.7% | 212 |
| Laurus Labs LimitedLAURUSLABSLAURUSLABS | ₹1,07,176 Cr | ₹1,09,573 Cr | ₹7,270 Cr | ₹2,034 Cr | 26.1% | ₹1,093 Cr | 13.1% | 21.3% | 18.2% | 263 |
| Mankind Pharma LimitedMANKINDMANKIND | ₹1,04,696 Cr | ₹1,11,007 Cr | ₹14,738 Cr | ₹3,827 Cr | 25.3% | ₹2,068 Cr | 13.6% | 14.2% | 12.5% | 117 |
| Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA | ₹97,389 Cr | ₹1,05,065 Cr | ₹34,935 Cr | ₹7,085 Cr | 20.3% | ₹3,713 Cr | 10.4% | 14.7% | 9.9% | 252 |
| Lupin LimitedLUPINLUPIN | ₹92,866 Cr | ₹98,777 Cr | ₹29,967 Cr | ₹9,538 Cr | 31.5% | ₹5,529 Cr | 19.2% | 34.2% | 26.9% | 181 |
| Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK | ₹65,781 Cr | ₹65,781 Cr | ₹17,737 Cr | ₹4,797 Cr | 26.9% | ₹1,496 Cr | 8% | 37.8% | 0% | 83 |
| Alkem Laboratories LimitedALKEMALKEM | ₹62,431 Cr | ₹64,055 Cr | ₹15,081 Cr | ₹3,032 Cr | 20.4% | ₹2,158 Cr | 16% | 21.5% | 17.8% | 152 |
| Biocon LimitedBIOCONBIOCON | ₹60,413 Cr | ₹75,238 Cr | ₹17,321 Cr | ₹3,536 Cr | 20.4% | ₹495 Cr | 2.2% | 3.9% | 1.4% | 85 |
| Abbott India LimitedABBOTINDIAABBOTINDIA | ₹56,901 Cr | — | ₹4,310 Cr | ₹921 Cr | 27.3% | ₹691 Cr | 22.4% | 44.1% | 34.5% | 110 |
| Ipca Laboratories LimitedIPCALABIPCALAB | ₹49,299 Cr | ₹50,003 Cr | ₹10,126 Cr | ₹2,232 Cr | 20.5% | ₹1,310 Cr | 12.3% | 17.8% | 15.2% | 308 |
| Gland Pharma LimitedGLANDGLAND | ₹47,428 Cr | ₹47,671 Cr | ₹6,725 Cr | ₹1,751 Cr | 25.3% | ₹1,129 Cr | 16% | 14.8% | 10.5% | 255 |
Documents link to external sources (exchange filings, company investor pages).
Corporate actions, results dates and filings will appear here once ingested.
Consolidated figures
| Ratio | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Margins | ||||
| Gross margin % | 36.2% | 34.2% | 47.6% | 40.7% |
| EBITDA margin % | 19.7% | 18.4% | 17.1% | 21.8% |
| EBIT margin % | 18.6% | 16.2% | 10.8% | 17.1% |
| PAT margin % | 19% | 14.2% | 13.5% | 14.8% |
| Working capital | ||||
| Receivable days | — | — | — | — |
| Inventory days | 129 | 156 | 226 | 174 |
| Payable days | — | — | — | — |
| NWC days | — | — | — | — |
| Leverage | ||||
| Current ratio | 4.43 | 2.57 | 1.69 | 1.59 |
| Debt to EBITDA | — | — | — | — |
| Debt to equity | — | — | — | — |
| Interest coverage | 15 | 15.5 | 4.4 | 7.6 |
| Asset turnover | 0.54 | 0.51 | 0.56 | 0.54 |
| Return ratios | ||||
| Return on assets % | 10.2% | 7.3% | 7.5% | 8% |
| Return on capital employed % | 14.7% | 16.2% | 20.8% | 24.9% |
| Return on equity % | — | — | — | — |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
| Holder (%) | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| 62.99% | 62.99% | 63.04% | 63.04% | 63.11% | 64.11% | 62.85% | 62.59% | |
| 6.09% | 6.09% | 6.62% | 7.21% | 7.71% | 7.04% | 7.24% | 5.25% | |
| 0% | 0% | 0.09% | 0.39% | 0.41% | 0.35% | 0.27% | 0.26% | |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 30.92% | 30.92% | 30.25% | 29.36% | 28.77% | 28.5% | 29.64% | 31.9% | |
| No. of shareholders | 507 | 523 | 534 | 549 | 554 | 575 | 607 | 709 |
Promoter holding down 0.4 percentage points since Sep 2024.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 15 Sept 2026 | QUARKS TECHNOSOFT PRIVATE LIMITED | Bulk | BSE | Buy | 82,800 | ₹289.34 | ₹2.40 Cr |
| 15 Sept 2026 | CRAFT EMERGING MARKET FUND PCC-ELITE CAPITAL FUND | Bulk | BSE | Sell | 79,800 | ₹283.74 | ₹2.26 Cr |
| 15 Sept 2026 | NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND | Bulk | BSE | Sell | 75,000 | ₹280.51 | ₹2.10 Cr |
| 15 Sept 2026 | QUARKS TECHNOSOFT PRIVATE LIMITED | Bulk | BSE | Sell | 1,200 | ₹297.10 | ₹0.04 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
No scheme among the 32 fund houses on record reported a position in Trident Lifeline Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Acquisition
Board Meeting Intimation for Consideraration And Evaluate The Proposal To Raise Funds
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosure Under Regulation 30 Of SEBI (LODR)- Intimation Of Award
| Date | Category | Subject | Filing |
|---|---|---|---|
| 1 Oct 2026, 6:33 pm | Company Update Analyst / Investor Meet | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | |
| 30 Sept 2026, 6:44 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window |
| 30 Sept 2026, 6:42 pm | Company Update Acquisition | Announcement under Regulation 30 (LODR)-Acquisition |
| 29 Sept 2026, 7:06 pm | Board Meeting | Board Meeting Intimation for Consideraration And Evaluate The Proposal To Raise Funds |
| 28 Sept 2026, 3:52 pm | AGM/EGM AGM | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 28 Sept 2026, 12:28 pm | Company Update Analyst / Investor Meet | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 16 Sept 2026, 1:54 pm | Company Update Analyst / Investor Meet | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation |
| 8 Sept 2026, 7:02 pm | Company Update General | Disclosure Under Regulation 30 Of SEBI (LODR)- Intimation Of Award |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 32 | 45 | 87 | 129 | |
| COGS | 20 | 29 | 46 | 76 |
| Gross profit | 11 | 15 | 41 | 53 |
| 5 | 7 | 27 | 24 | |
| 6 | 8 | 15 | 28 | |
| OPM % | 19.7% | 18.4% | 17.1% | 21.8% |
| Depreciation | 0 | 1 | 5 | 6 |
| Interest | 0 | 1 | 4 | 4 |
| 1 | 2 | 8 | 9 | |
| Profit before tax | 7 | 9 | 14 | 27 |
| Tax | 1 | 3 | 3 | 8 |
| Tax % | 8.5% | 31.7% | 22.9% | 28.9% |
| 6 | 6 | 12 | 19 | |
| PAT margin % | 19% | 14.2% | 13.5% | 14.8% |
| EPS (₹) | 6.2 | 5.2 | 10.2 | 16.3 |
| Annual report | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | — | — | — | — |
| Reserves | — | — | — | — |
| Borrowings | — | — | — | — |
| 59 | 87 | 156 | 237 | |
| Total equity & liabilities | 59 | 87 | 156 | 237 |
| Fixed assets | — | — | 35 | 43 |
| CWIP | — | — | — | — |
| Investments | 3 | 4 | 11 | 8 |
| 56 | 83 | 110 | 186 | |
| Total assets | 59 | 87 | 156 | 237 |
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| -17 | 2 | -10 | 5 | |
| -7 | -20 | -14 | -37 | |
| 38 | 11 | 20 | 34 | |
| Net cash flow | 14 | -7 | -4 | 2 |
| Free cash flow | -22 | -16 | -21 | -32 |
| CFO / Operating profit % | -279% | 27.2% | -68.9% | 16.7% |